4F-MPH
4-fluoromethylphenidate
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
4F-MPH (4-fluoromethylphenidate) is a synthetic stimulant of the substituted phenidate class. It is a fluorinated structural analog of methylphenidate, approximately twice as potent per milligram.[1] It blocks the clearance of dopamine and norepinephrine from the brain's synapses, producing the focused, alert stimulation characteristic of phenidate compounds.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
methylphenidate, ethylphenidate, isopropylphenidate +1 moremethylphenidate, ethylphenidate, isopropylphenidate, other phenidate analogs show less
4F-MPH appeared on online research chemical markets in 2015, emerging after the United Kingdom banned ethylphenidate.[1] The EMCDDA issued an early warning in November 2015,[2] and it spread quickly as a grey-market cognitive enhancer and productivity aid.[3] It remains unscheduled at the international level but controlled in the UK, Canada, and several other jurisdictions.
Subjective effects include increased focus, wakefulness, rapid thinking, appetite suppression, and emotional flattening. The experience is characteristically mechanical — dry, task-oriented stimulation with minimal warmth or euphoria, closer to an amplified work state than a recreational high. Compulsive redosing, anxiety at higher doses, and a dysphoric comedown disproportionate to the modest high are common unwanted effects.[3]
4F-MPH carries high dependence potential driven by strong DAT blockade,[4] and elevated heart rate and blood pressure are the primary acute dangers.[5] Its greater potency than methylphenidate means cardiovascular effects can appear at lower doses; one confirmed overdose required emergency sedation.[6] The evidence base is extremely thin — current understanding rests on two in vitro studies, two case reports, and community self-reports.
History[edit]
Discovery
4-Fluoromethylphenidate appeared on online research chemical markets in 2015 after the United Kingdom banned ethylphenidate.[1] It was not developed by pharmaceutical researchers — it emerged from grey-market synthesis as a replacement compound. The first published study confirmed its mechanism and found that potency varied significantly between commercial batches depending on the molecular form they contained.[1]
Regulatory response and detection
The EMCDDA issued an early warning for 4F-MPH in November 2015.[2] It appeared in a US fatality in 2018 — the first American death with 4F-MPH on the certificate, though seven other substances were present.[7] The United Kingdom classified it Class B and Canada made it controlled, both in 2017.[8]
Market positioning
4F-MPH has been sold online as a cognitive enhancer and productivity aid, positioned as a "functional" stimulant separate from recreational drugs.[3] Some users take it to self-medicate ADHD symptoms when prescription stimulants are unavailable.[3][9] This framing understates the risk — its strong selectivity for dopamine transporters predicts substantial abuse liability regardless of user intent.
Chemistry[edit]
Structural class
4F-MPH belongs to the substituted phenidate class — the same chemical family as methylphenidate. It differs by a single fluorine atom added to the phenyl ring, a modification that roughly doubles its potency.[1] Its molecular formula is C₁₄H₁₈FNO₂ (molecular weight 251.30 g/mol as a free base).
Thermal instability
Phenidate compounds including 4F-MPH break down at the temperatures reached during smoking or vaping.[10] Heating produces degradation products rather than intact 4F-MPH, making those routes both unreliable and potentially harmful. Published physical properties — including a melting point of approximately 147–148 °C for the salt form — derive from commercial sources and computational models rather than peer-reviewed measurement.[11]
Pharmacology[edit]
Mechanism of action
4F-MPH blocks the dopamine and norepinephrine transporters, preventing those neurotransmitters from being cleared from the synapse and amplifying their signals.[1][12] It does not trigger neurotransmitter release — this separates phenidate-class compounds from amphetamines, which actively push dopamine and norepinephrine out of nerve cells.[13]
The active form of 4F-MPH is roughly twice as potent as methylphenidate at the DAT and nearly three times as potent at the norepinephrine transporter.[1] Its strong selectivity for dopamine over serotonin is associated with higher reinforcement potential and abuse liability.[4]
Pharmacokinetics
No human pharmacokinetic studies have been published for 4F-MPH. Duration estimates come from community reports: oral doses take effect in 30–60 minutes and last 4–8 hours; insufflation produces onset in 10–30 minutes with effects lasting 3–6 hours.[14] Animal studies identified metabolites consistent with methylphenidate's known breakdown pathway.[15]
Neuroscience[edit]
Where it acts
No neuroimaging studies have been conducted with 4F-MPH — all understanding is extrapolated from the methylphenidate class. As a potent dopamine and norepinephrine blocker, 4F-MPH amplifies dopamine signaling along the brain's reward circuit, driving motivation and reinforcement. At moderate doses it also enhances prefrontal dopamine and norepinephrine, supporting focus enhancement and thought organization.
Why it matters
There is a narrow window between helpful and harmful: moderate doses sharpen focus, while higher doses impair it, producing anxiety and thought acceleration. Separately, dopamine amplification explains compulsive redosing — dopamine sharpens the drive to repeat an action without proportionally increasing the pleasure from it.citation needed
Does 4F-MPH occupy dopamine transporters in greater proportions than methylphenidate at lower doses, as its lab potency predicts? Does repeated use lead to escalating tolerance or diminishing returns? Does the fluorine atom meaningfully extend how long it stays active in the body? No substance-specific data exist for any of these questions.
Subjective Effects[edit]
4F-MPH produces a distinctly "functional" stimulant experience — task-oriented cognitive sharpening and physical activation with little warmth or euphoria. Emotional tone tends toward flattening during the active phase, often followed by a dysphoric offset disproportionate to the modest high. With increasing doses the experience tips into anxious overstimulation.[3]
Relative to methylphenidate, 4F-MPH is qualitatively similar but more potent per milligram, with a narrower margin between useful and uncomfortable. Compared to amphetamine-type stimulants, it is less euphoriant and more "mechanical" in character — consistent with its reuptake-inhibitor mechanism and the absence of direct neurotransmitter release.[12]
Effect Grid
Clear stimulant effects are present — sustained focus enhancement, wakefulness, thought acceleration, and pronounced appetite suppression. This is the dose range most commonly reported for cognitive enhancement use. Mild euphoria is possible, particularly on initial exposures, though 4F-MPH is generally described as less euphoriant than amphetamine-type stimulants.
Pupil dilation becomes apparent. Heart rate is noticeably elevated. Mild vasoconstriction may produce cool extremities. Emotional suppression is clearly present — reduced emotional range and affective flattening are characteristic of this tier. Bruxism and mild excessive sweating may begin.
Aftereffects are disproportionately long relative to the active phase. Insomnia is likely if taken after midday. Post-use irritability, low mood, and cognitive fatigue are common during offset. Compulsive redosing urge begins to emerge, particularly via insufflated administration.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Pupil dilation · Insomnia · Dry mouth · Heart rate perception changes · Physical fatigue · Dehydration sensation · Excessive sweating · Spontaneous body sensations · Muscle tension · Restlessness · Sexual arousal enhancement · Bodily lightness · Headache · Respiratory stimulation · Temperature dysregulation · Motor control enhancement · Nausea · Bruxism · Dizziness · Constipation · Nasal congestion · Tingling / electric sensations · Trembling
Heart rate perception changes · Physical fatigue · Dehydration sensation · Excessive sweating · Spontaneous body sensations · Muscle tension · Restlessness · Sexual arousal enhancement · Bodily lightness · Headache · Respiratory stimulation · Motor control enhancement · Nausea · Bruxism · Dizziness · Constipation · Nasal congestion · Tingling / electric sensations · Trembling
Analysis enhancement · Motivation enhancement · Cognitive euphoria · Immersion enhancement · Information processing enhancement · Suggestibility suppression · Motivation suppression · Aesthetic enhancement · Thought connectivity · Memory enhancement · Thought deceleration · Cognitive impairment · Multiple thought streams · Thought loops · Thought disorganization
Information processing enhancement · Suggestibility suppression · Motivation suppression · Aesthetic enhancement · Thought connectivity · Memory enhancement · Thought deceleration · Cognitive impairment · Multiple thought streams · Thought loops · Thought disorganization
Irritability · Anhedonia · Dysphoria · Emotional lability · Empathy suppression
Empathy suppression
Communication enhancement · Self-control enhancement · Sociability enhancement · Automaticity · Sociability suppression
Sociability suppression
Timeline
Gradual build of alertness and mild stimulation. Effects may be subtle initially — a faint sharpening of attention that could be mistaken for placebo.
Full cognitive enhancement with sustained focus, thought acceleration, and appetite suppression. Emotional flattening and cardiovascular effects (elevated heart rate, vasoconstriction) are present. Compulsive redosing urge may emerge.
Stimulation fades progressively. Dysphoric rebound begins — irritability, low mood, and cognitive fatigue replace the productive clarity of the peak.
Residual wakefulness and appetite suppression persist well beyond active effects. Mood may be low. Insomnia is common even when other effects have resolved.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 5 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- methylphenidate · ethylphenidate · isopropylphenidate
Toxicity
Acute toxicity
No lethal dose has been established for 4F-MPH in any species, and no dose-finding toxicological studies exist.safety citation needed The compound can cause toxicity serious enough to require emergency care: a 26-year-old woman who insufflated it for one week developed agitation, confused mental state, and cardiovascular abnormalities — requiring intravenous sedation and antipsychotic medication.[6]
One US death listed 4F-MPH on the certificate, but seven other substances were also present — including methamphetamine and a synthetic opioid — so 4F-MPH's independent contribution cannot be determined.[7]
Cardiovascular toxicity
Elevated heart rate, increased blood pressure, and irregular heart rhythm are the primary acute dangers, extrapolated from the methylphenidate class.[5] Rare but documented outcomes for this class include heart attack and sudden cardiac death. Because 4F-MPH is 2–3 times more potent at the relevant transporters,[1] cardiovascular effects may be stronger at equivalent milligram doses than with methylphenidate.
Pre-existing heart conditions substantially increase risk. No 4F-MPH-specific cardiovascular safety data have been published.safety citation needed
Chronic toxicity
No data exist on chronic toxicity. Long-term use of methylphenidate-class stimulants is associated with sustained cardiovascular stress and disruption of dopamine signaling.[5] Whether 4F-MPH's greater potency accelerates this process is unknown.inferred
Psychological risks
High doses and sleep deprivation can produce paranoia, hallucinations, and delusional thinking. Methylphenidate-class effects applicable to 4F-MPH include anxiety, agitation, restlessness, worsening of mood disorders, and triggering of manic episodes.[5] The confirmed mono-intoxication case exhibited agitation and altered mental state requiring antipsychotic medication.[6]
Compulsive redosing is widely reported, especially via insufflation where faster onset strengthens the urge.[14] Dysphoria, irritability, and amotivation after use are common offset effects, worsening with dose and frequency.[14]
Tolerance and dependence
No published experimental data on tolerance or dependence exist for 4F-MPH — all characterization is inferred from the class. Methylphenidate maintains robust self-administration in primates comparable to cocaine,[16] and 4F-MPH's roughly twofold greater potency at the DAT suggests at least equivalent reinforcing power.
Abuse potential among dopamine reuptake inhibitors correlates with how selectively they act on dopamine relative to serotonin.[4] 4F-MPH's selectivity ratio places it in the high-liability category alongside cocaine and methylphenidate. Compulsive redosing is a recognized risk in community reports.[14]
Drug interactions
Tramadol
This combination carries a "lethal" severity designation. Tramadol lowers the seizure threshold and has weak serotonin activity; combining it with a potent stimulant adds cardiovascular strain on top of seizure risk.safety citation needed
MDMA
Designated "dangerous." 4F-MPH's dopamine and norepinephrine stimulation combines with MDMA's serotonin release to produce additive increases in heart rate, blood pressure, and body temperature.safety citation needed
Alcohol
When methylphenidate is taken with alcohol, an enzyme reaction produces ethylphenidate — a distinct psychoactive compound — alongside increased early drug exposure and potentiated euphoria.[17] Whether the same reaction occurs with 4F-MPH is structurally plausible but unconfirmed. Severity designation: "unknown."
Other stimulants
Combining 4F-MPH with amphetamines, cocaine, or cathinones produces additive cardiovascular and CNS stimulant effects. The only confirmed US fatality involving 4F-MPH occurred in a polydrug context that included amphetamine and methamphetamine.[7]
MAOIs
Combining 4F-MPH with monoamine oxidase inhibitors — drugs that block the breakdown of dopamine and norepinephrine — risks a dangerous spike in blood pressure from the combined accumulation of these neurotransmitters.inferred
Contraindications
No 4F-MPH-specific contraindication data exist. The following are inferred from the methylphenidate class[5] and apply with at least equal weight given 4F-MPH's greater potency.
Absolute:
- Concurrent MAOI use — risk of dangerous blood pressure crisis
- Severe heart disease (structural heart disease, recent heart attack, uncontrolled irregular heart rhythm) — stimulation may trigger fatal cardiac events
- Pheochromocytoma — a tumor that releases epinephrine-like chemicals; 4F-MPH amplifies these to dangerous levels
Relative:
- High blood pressure — dose-dependent blood pressure elevation worsens uncontrolled hypertension
- Anxiety disorders — norepinephrine amplification worsens symptoms[6]
- History of psychosis or bipolar disorder — stimulants can trigger psychotic or manic episodes
- Seizure disorders — stimulants may lower the seizure threshold
- Liver impairment — reduced clearance is possible if metabolism parallels methylphenidate
- Pregnancy and breastfeeding — no reproductive data exist; contraindicated by precaution
All contraindications are inferred from the class pending substance-specific research.inferred
Harm Reduction[edit]
Forms & Identification
4F-MPH circulates as a white crystalline powder sold by online research chemical vendors. Potency can vary significantly between batches — even from the same supplier — because the ratio of the active molecular form to the inactive one differs.[1] A batch with a higher proportion of the active form will feel substantially stronger at the same weighed dose.
Reagent testing can confirm a phenidate-class compound is present but cannot identify specific analogs or measure the active-to-inactive ratio.
Guidelines
- Test every batch with a reagent kit to confirm a phenidate-class compound is present
- Start with a low oral dose — potency varies between batches due to diastereomeric composition
- Weigh doses with a milligram-precision scale; do not estimate
- Set a firm cutoff time at least 8 hours before intended sleep
- Eat a full meal before dosing; appetite suppression often prevents eating during the active phase
- Stay hydrated — stimulant effects mask thirst signals
- Avoid redosing; if redosing, halve the original dose and limit to one additional administration
- Do not switch to insufflation mid-session for a "boost" — this route carries greater compulsive redosing risk
Set & Setting
4F-MPH's stimulant character suits structured, task-oriented environments. Its tendency toward emotional suppression and anxious overstimulation at higher doses makes it poorly suited to social or emotionally demanding settings.
Insufflation produces faster, sharper onset and greater compulsive redosing liability. Oral administration offers a more controlled arc. Setting a firm end time for the session protects sleep — residual stimulation can persist for hours after the subjective peak.
Aftercare & integration. The 4F-MPH comedown commonly brings dysphoria, irritability, and amotivation lasting 12–24 hours, often feeling disproportionate to the modest high.[14] Prioritize sleep — use blackout curtains, avoid screens, and consider magnesium or melatonin if sleep onset is difficult.
Eat a substantial meal as soon as appetite returns. Avoid caffeine or other stimulants in the recovery window — they prolong cardiovascular stress and delay emotional baseline return. If dysphoria persists beyond 48 hours or use frequency is increasing, re-evaluate the pattern rather than redose.
Recovery & Support
4F-MPH's compulsive redosing profile and high DAT selectivity make escalating use a recognized risk. If use has shifted from occasional to daily or near-daily, or if stopping produces significant fatigue, low mood, or cravings, professional support is warranted.
SAMHSA's National Helpline (1-800-662-4357) provides free referrals in the United States. SMART Recovery and stimulant-specific support groups offer structured frameworks for examining use patterns. A healthcare provider familiar with stimulant use disorders can assess whether clinical intervention is needed.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, irregular or pounding heartbeat, seizure, loss of consciousness, severe confusion, or body temperature hot to the touch through clothing all indicate a medical emergency — not just an uncomfortable stimulant experience.
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present
- 2. Keep the person seated or lying down in a cool, quiet environment
- 3. Do not restrain them unless they are in immediate physical danger
- 4. Remove excess clothing and apply cool water if overheating is suspected
- 5. Do not induce vomiting
What to tell the dispatcher: Name the substance (4-fluoromethylphenidate / 4F-MPH), approximate dose and time taken, route of administration, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No specific reversal agent exists for stimulant intoxication. Hospital treatment is supportive — typically intravenous sedation with benzodiazepines, as documented in the confirmed mono-intoxication case.[6]
Legal Status[edit]
4F-MPH is not controlled under international drug treaties.[2] National responses have varied since EMCDDA early warnings began in November 2015, and legal status differs substantially by jurisdiction.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not federally scheduled | The Federal Analogue Act may apply if 4F-MPH is intended for human consumption, as methylphenidate is Schedule II. Alabama has enacted state-level Schedule I control[2] |
| United Kingdom | Class B controlled drug | Scheduled 31 May 2017 under the Psychoactive Substances Act framework[8] |
| Canada | Controlled substance | Controlled since 5 May 2017[8] |
| Germany | Controlled under NpSG | Listed under the New Psychoactive Substances Act since November 2016. Reports of accidental re-legalization via regulatory omission in September 2022 could not be verifiedcitation needed |
| Australia | Likely Schedule 9 | No 4F-MPH-specific scheduling document identified; classification inferred from analogue provisions of the Poisons Standardcitation needed |
Individual EU member states have enacted varied responses beyond the EMCDDA notification.
Analog act considerations
In the United States, 4F-MPH's structural similarity to methylphenidate (Schedule II) makes it a candidate for prosecution under the Federal Analogue Act if intended for human consumption. The "research chemical" labeling vendors use attempts to circumvent this — but legal effectiveness varies by jurisdiction and judicial interpretation.
Legal status changes frequently and varies by jurisdiction. This information is not legal advice — verify current local laws before possession or purchase.
references
- [1] ^abcdefghiMcLaughlin G, Morris N, Kavanagh PV, Power JD, Dowling G, Twamley B, O'Brien J, Hessman G, Murphy B, Walther D, Partilla JS, Baumann MH, Brandt SD (2017) Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)-threo and (±)-erythro diastereomers — Drug Testing and Analysis doi:10.1002/dta.2167
- [2]
- [3]
- [4] ^abcLiechti ME (2015) Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling — Swiss Medical Weekly doi:10.4414/smw.2015.14043
- [5]
- [6]